NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

Spotlight Medical secures €6.2M for to commercialise AI-powered prognosis tests

Spotlight Medical founders
Picture credits: Spotlight Medical

French startup Spotlight Medical, a precision medicine startup solving the critical issue of inadequate cancer treatments, has raised €6.2 million in seed funding. The round was led by Kurma Partners (which backed Gyanmed Robotics and Charles.co) and Heal Capital.

This funding will enable the startup to bring its first AI-based prognosis test to the clinic. This is a milestone in the commercialisation of AI-based solutions for cancer treatment. 

Investors’ views

Kurma Partners and Heal Capital recognise the transformative potential of Spotlight Medical’s technology. “We were impressed by the quality of the team and by their unique technology, quite different from what we usually see in the field of precision oncology,” said Benjamin Belot from Kurma Partners. Christian Lautner from Heal Capital added, “We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients’ lives.”

“We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment,” said Sylvain Berlemont, CEO of Spotlight Medical. “This investment will accelerate our mission to harness the power of AI in analysing patient data, providing physicians with the insights they need to make more informed treatment decisions.”

What does the company do?

Spotlight Medical was founded earlier this year by Sylvain Berlemont, Marvin Lerousseau, and Grégoire Gessain. It aims to ensure that no patient is over or undertreated, ultimately improving cancer outcomes. 

The company develops clinical tests that exploit the vast amount of information contained in patient data. By using advanced AI algorithms, the company aims to provide the first concrete AI-based solution for cancer patients, significantly enhancing the precision of cancer treatment. This ensures personalised and effective care for each individual, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, it creates impactful tests that address critical unmet clinical needs, opening a new era in cancer care.

“We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment,” said Sylvain Berlemont, CEO of Spotlight Medical. “This investment will accelerate our mission to harness the power of AI in analysing patient data, providing physicians with the insights they need to make more informed treatment decisions.”

What do we think about Spotlight Medical?

The company is poised for a significant impact in precision oncology with its seed funding. The investment will fast-track the commercialisation of its AI-based prognosis test, enhancing cancer treatment precision. 

Founded by experts, the startup leverages advanced AI to provide personalised care, aiming to improve patient outcomes. By collaborating with physicians, Spotlight Medical addresses critical clinical needs, promising a transformative future in cancer care with more effective and tailored treatments.

Related Posts
Total
0
Share

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you